India, March 11 -- Shares of Arvinas, Inc. (ARVN) slipped over 50% on Tuesday morning after the company and Pfizer Inc. (PFE) announced mixed results in late-stage study.
ARVN is currently trading at $8.66, down $8.90 or 50.68%, on the Nasdaq. The stock opened its trading at $10.58 after closing Monday at $17.56. The stock has traded between $9.00 and $46.62 in the past 52-week period.
The study is designed to evaluate the companies' vepdegestrant compared to AstraZeneca's fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The trial met its primary goal in the estrogen rece...